Michael Davidson Sells 183,332 Shares of NewAmsterdam Pharma (NASDAQ:NAMS) Stock

NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS) CEO Michael Davidson sold 183,332 shares of the business’s stock in a transaction that occurred on Thursday, February 26th. The stock was sold at an average price of $33.71, for a total transaction of $6,180,121.72. Following the sale, the chief executive officer directly owned 174,144 shares of the company’s stock, valued at approximately $5,870,394.24. This trade represents a 51.29% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website.

NewAmsterdam Pharma Price Performance

Shares of NewAmsterdam Pharma stock traded down $0.73 on Thursday, hitting $34.28. 900,936 shares of the company’s stock traded hands, compared to its average volume of 634,742. NewAmsterdam Pharma Company N.V. has a one year low of $14.06 and a one year high of $42.00. The stock has a market capitalization of $3.89 billion, a PE ratio of -19.81 and a beta of 0.06. The firm’s 50-day moving average price is $34.05 and its two-hundred day moving average price is $32.88.

NewAmsterdam Pharma (NASDAQ:NAMS) last issued its earnings results on Wednesday, February 18th. The company reported ($0.63) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.40) by ($0.23). The company had revenue of $0.03 million for the quarter, compared to the consensus estimate of $0.92 million. NewAmsterdam Pharma had a negative return on equity of 26.67% and a negative net margin of 906.22%. On average, analysts forecast that NewAmsterdam Pharma Company N.V. will post -1.75 earnings per share for the current fiscal year.

Hedge Funds Weigh In On NewAmsterdam Pharma

A number of institutional investors have recently added to or reduced their stakes in NAMS. Farther Finance Advisors LLC lifted its stake in NewAmsterdam Pharma by 4,425.0% in the 4th quarter. Farther Finance Advisors LLC now owns 724 shares of the company’s stock valued at $25,000 after purchasing an additional 708 shares during the last quarter. Wells Fargo & Company MN lifted its holdings in NewAmsterdam Pharma by 50.0% during the 4th quarter. Wells Fargo & Company MN now owns 900 shares of the company’s stock valued at $32,000 after purchasing an additional 300 shares during the last quarter. Mather Group LLC. bought a new position in shares of NewAmsterdam Pharma in the third quarter valued at about $28,000. Thurston Springer Miller Herd & Titak Inc. acquired a new stake in shares of NewAmsterdam Pharma during the 3rd quarter worth about $30,000. Finally, Navalign LLC bought a new stake in shares of NewAmsterdam Pharma during the 4th quarter worth about $46,000. 89.89% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

NAMS has been the topic of several recent analyst reports. Wall Street Zen lowered NewAmsterdam Pharma from a “hold” rating to a “sell” rating in a report on Saturday, February 21st. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of NewAmsterdam Pharma in a research report on Thursday, February 19th. Guggenheim lifted their price objective on NewAmsterdam Pharma from $41.00 to $45.00 and gave the company a “buy” rating in a report on Thursday, February 19th. Needham & Company LLC increased their target price on NewAmsterdam Pharma from $46.00 to $48.00 and gave the stock a “buy” rating in a research note on Wednesday, February 18th. Finally, Stifel Nicolaus raised their target price on shares of NewAmsterdam Pharma from $44.00 to $50.00 and gave the stock a “buy” rating in a report on Tuesday, December 16th. One analyst has rated the stock with a Strong Buy rating, nine have assigned a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $47.00.

About NewAmsterdam Pharma

NewAmsterdam Pharma, Inc is a clinical‐stage biopharmaceutical company focused on discovering and developing novel small‐molecule therapies for cardiometabolic diseases. The company’s research efforts are aimed at addressing key unmet needs in metabolic syndrome, obesity and type 2 diabetes by modulating pathways involved in glucose regulation, energy homeostasis and lipid metabolism.

The company’s development pipeline features multiple small‐molecule candidates at various stages of preclinical and clinical evaluation.